Biofrontera (BFRI) Non-Current Assets (2020 - 2025)
Biofrontera's (BFRI) quarterly Non-Current Assets came in at $10.5 million in Q4 2025, up 648.11% year-on-year from $1.4 million in Q4 2024, and up 946.01% quarter-over-quarter from $1.0 million in Q3 2025.
Biofrontera (BFRI) Non-Current Assets (2020 - 2025) Analysis & Trends
Biofrontera's Non-Current Assets history runs 6 years deep, the most recent figure standing at $10.5 million for Q4 2025.
- On a quarterly basis, Non-Current Assets rose 648.11% year-over-year to $10.5 million in Q4 2025; TTM through Dec 2025 was $14.1 million, a 22.22% increase from a year earlier, with the FY2025 full-year figure at $10.5 million, up 648.11% from the prior year.
- Non-Current Assets climbed to $10.5 million in Q4 2025 per BFRI's latest filing, from $1.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.5 million in Q4 2025 and bottomed at -$46.4 million in Q4 2021.
- The 5-year median for Non-Current Assets is $4.5 million (2023), against an average of $1.5 million.
- Across the five-year window, Non-Current Assets slumped 1117.38% in 2021 and surged 648.11% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at -$46.4 million in 2021, then surged by 116.68% to $7.7 million in 2022, then tumbled by 37.28% to $4.9 million in 2023, then plunged by 71.16% to $1.4 million in 2024, then jumped by 648.11% to $10.5 million in 2025.
- Per Business Quant, the three latest BFRI Non-Current Assets figures stand at $10.5 million (Q4 2025), $1.0 million (Q3 2025), and $1.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn | 10.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.48 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 4.10 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | 7.74 Mn |
| Sep 30, 2022 | 6.57 Mn |
| Jun 30, 2022 | 6.65 Mn |
| Mar 31, 2022 | 6.67 Mn |
| Dec 31, 2021 | -46.41 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Dec 31, 2020 | 4.56 Mn |